madman
Super Moderator
* Panelists address the risk of polycythemia associated with testosterone therapy, particularly injectable formulations, and emphasize the importance of monitoring hematocrit changes relative to baseline values rather than absolute thresholds alone
Moderated by Manoj Monga, MD, FACS, FRCS, Professor and Chair, Department of Urology, University of California, San Diego, La Jolla, California, this panel discussion explores testosterone replacement therapy, with ongoing debate surrounding safety, efficacy, formulation selection, and appropriate patient selection. The panel examines practical considerations in the evaluation and management of hypogonadism, drawing on clinical experience, available evidence, and emerging therapeutic options.
The discussion begins with clinical scenarios highlighting common challenges, including patients with low testosterone levels, comorbidities such as diabetes, fatigue, and concerns regarding cardiovascular risk. Panelists address the risk of polycythemia associated with testosterone therapy, particularly injectable formulations, and emphasize the importance of monitoring hematocrit changes relative to baseline values rather than absolute thresholds alone. Dose adjustment and formulation switching are discussed as preferred strategies over repeated therapeutic phlebotomy.
Various testosterone delivery methods are compared, including injections, topical therapies, pellets, and newer FDA-approved oral formulations. Monitoring strategies are reviewed, including laboratory timing and the role of testosterone levels, complete blood count, prostate-specific antigen, and liver function testing.
Lifestyle modification is emphasized as a critical component of testosterone management, with exercise and weight loss discussed as having a significant impact on symptoms and overall health. The role of glucagon-like peptide-1 receptor agonists is raised in the context of body composition and metabolic health. The panel also explores the use of enclomiphene as an alternative approach in men with borderline testosterone levels, highlighting physiologic advantages and fertility preservation.
Audience questions prompt discussion of trial discontinuation when symptomatic benefit is absent, monitoring intervals, and emerging advocacy efforts to expand testosterone coverage. The group shares perspectives on regulatory evolution and future directions in the management of hypogonadism.
Moderated by Manoj Monga, MD, FACS, FRCS, Professor and Chair, Department of Urology, University of California, San Diego, La Jolla, California, this panel discussion explores testosterone replacement therapy, with ongoing debate surrounding safety, efficacy, formulation selection, and appropriate patient selection. The panel examines practical considerations in the evaluation and management of hypogonadism, drawing on clinical experience, available evidence, and emerging therapeutic options.
The discussion begins with clinical scenarios highlighting common challenges, including patients with low testosterone levels, comorbidities such as diabetes, fatigue, and concerns regarding cardiovascular risk. Panelists address the risk of polycythemia associated with testosterone therapy, particularly injectable formulations, and emphasize the importance of monitoring hematocrit changes relative to baseline values rather than absolute thresholds alone. Dose adjustment and formulation switching are discussed as preferred strategies over repeated therapeutic phlebotomy.
Various testosterone delivery methods are compared, including injections, topical therapies, pellets, and newer FDA-approved oral formulations. Monitoring strategies are reviewed, including laboratory timing and the role of testosterone levels, complete blood count, prostate-specific antigen, and liver function testing.
Lifestyle modification is emphasized as a critical component of testosterone management, with exercise and weight loss discussed as having a significant impact on symptoms and overall health. The role of glucagon-like peptide-1 receptor agonists is raised in the context of body composition and metabolic health. The panel also explores the use of enclomiphene as an alternative approach in men with borderline testosterone levels, highlighting physiologic advantages and fertility preservation.
Audience questions prompt discussion of trial discontinuation when symptomatic benefit is absent, monitoring intervals, and emerging advocacy efforts to expand testosterone coverage. The group shares perspectives on regulatory evolution and future directions in the management of hypogonadism.
